Merck & Co. Inc. unveiled promising results from the Phase 2 portion of the waveLINE-003 trial involving their investigational drug zilovertamab vedotin. Administered at a dose of 1.75 mg/kg in combination with rituximab, gemcitabine, and oxaliplatin, the treatment demonstrated significant antitumor activity and a complete response rate in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Dr. Gregory Lubiniecki from Merck Research Laboratories highlighted the manageable safety profile and potential of this ROR1-directed antibody-drug conjugate to treat multiple hematologic malignancies. Dr. Philippe Armand of the Dana-Farber Cancer Institute noted the encouraging outcomes for patients, emphasizing the need for additional treatment options for those with relapsed/refractory DLBCL. The trial's success supports further research, with the Phase 3 portion already underway.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.